MABE1529MI
MilliporeSigma™ BRD7, Rat, Unlabeled, Clone: BRM203,
Manufacturer: MilliporeSigma™
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | MABE1529MI-Each-of-1 | In Stock | ₹ 42,968.31 |
MABE1529MI - Each of 1
In Stock
Quantity
1
Base Price: ₹ 42,968.31
GST (18%): ₹ 7,734.296
Total Price: ₹ 50,702.606
Antigen
BRD7
Classification
Monoclonal
Concentration
Please refer to lot specific datasheet.
Formulation
Purified rat monoclonal IgG2aκ antibody in buffer containing 0.1M Tris-Glycine (pH 7.4), 150mM NaCl with 0.05% Sodium Azide.
Gene Accession No.
Q9NPI1
Immunogen
Recombinant human BRD7.
Quantity
100 μg
Research Discipline
Epigenetics & Nuclear Function
Gene ID (Entrez)
NP_001167455
Target Species
Human
Form
Purified
Applications
Western Blot
Clone
BRM203
Conjugate
Unconjugated
Gene
BRD7, BP75, CELTIX1
Host Species
Rat
Purification Method
Protein G Purified
Regulatory Status
RUO
Primary or Secondary
Primary
Test Specificity
Clone BRM 2D3 detects human 75 kDa bromodomain protein, also known as protein CELTIX-1.
Content And Storage
Stable for 1 year at 2°-8°C from date of receipt.
Isotype
IgG2a κ
Related Products
Description
- Bromodomain-containing protein 7 (UniProt Q9NPI1; also known as 75kDa bromodomain protein, Protein CELTIX-1) is encoded by the BRD7 (also known as BP75, CELTIX1) gene (Gene ID 29117) in human
- BRD7 is a ubiquitously expressed single bromodomain-/BRD-containing member of the family of BRD-containing proteins
- BRD7 functions as a subunit of the SWI/SNF chromatin-remodeling complex involved in transcription regulation
- It also interacts with the well known tumor suppressor p53 to trans-activate genes involved in cell cycle arrest
- BRD7 is downregulated in colorectal carcinoma and nasopharyngeal carcinoma, and BRD7 overexpression is reported to inhibit nasopharyngeal carcinoma cell proliferation via cell cycle arrest by transcriptionally regulating ras/MEK/ERK, Rb/E2F, b-catenin and ERK pathways
- BRD7 mRNA has been identified as a silencing target of miR-300, overexpression of miR-300 promotes the proliferation, invasion and EMT of osteosarcoma cells through targeting BRD7 mRNA.